Company: EDSA
Filing Date: 2025-04-04
Form Type: DEF 14A
Source: 0001171843-25-002028
Chunk: 21

Company: Edesa Biotech, Inc.
Filing Date: 2025-04-04
Form: DEF 14A
Chunk 21
---
.

Anti-Hedging Policy

The company’s insider trading policy prohibits its directors, officers or employees, their family members and controlled entities to engage in hedging transactions. They are further prohibited from selling any securities of the Company that are not owned by such person at the time of the sale (a “short sale”); trading in standardized options (e.g., “calls” and “puts”) relating to the Company securities; or pledging as collateral or margin the Company’s securities.

Delinquent Section 16(a) Reports

Section 16(a) of the Exchange Act requires our directors, executive officers and persons who beneficially own more than 10% of our outstanding common shares to file reports with the SEC regarding their share ownership and changes in their ownership of our common shares. Based on our records and representations from our directors and executive officers, we believe that all Section 16(a) filing requirements applicable to our directors and executive officers were complied with during the fiscal year ended September 30, 2024, except for the following: due to administrative error, Pardeep Nijhawan filed a late Form 4 on January 12, 2024 to report a grant of restricted share units, which vested in full upon grant, pursuant to the 2019 Plan (as defined below) on January 8, 2024.

<div align='center'>13

INFORMATION CONCERNING EXECUTIVE OFFICERS</div>

The following table sets forth certain information regarding our current executive officers:

| Name                  
 Pardeep Nijhawan, MD  
 Stephen Lemieux (1)   |     | Age 
  54 
  49 |     | Position(s)                                               
 Director, Chief Executive Officer and Corporate Secretary 
 Chief Financial Officer                                   |     | Serves as an Officer or Director Since 
 June 7, 2019                           
 July 15, 2023                          |
|:----------------------|:----|----:|:----|:----------------------------------------------------------|:----|:---------------------------------------|
| Michael Brooks, Ph.D. |     |  46 |     | President                                                 |     | June 7, 2019                           |
| Peter Weiler (2)      |     |  56 |     | Chief Financial Officer, effective May 1, 2025            |     | -                                      |

(1) On April 3, 2025, Mr. Lemieux resigned as our Chief Financial Officer effective, May 1, 2025.